º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

Biotech company Nanovery moves to Newcastle science park to tap into regional talent

The firm which specialises in tech to improve the diagnosis of serious diseases has swapped London for Newcastle Helix

Left to right – Jurek Kozyra, co-founder and CEO of Nanovery, Luke Dunnett, property business manager at The Biosphere, coun Joyce McCarty, cabinet member for inclusive economy at Newcastle City Council.(Image: Nanovery/Newcastle City Council)

A biotech company has moved into Newcastle science park Helix after leaving London to tap into regional talent.

Nanovery specialises in nanorobotic technology to improve the diagnosis of some of the world’s most serious diseases,

Formed in 2018, it is developing nanorobots for a quick and easy test to help diagnose cancer and other diseases. It says its tests, based on DNA nanotechnology, costs less than tissue biopsy, while reducing risk to patients.

Read more: Find more technology stories here

The company, which was launched in London, moved to Newcastle last year to collaborate and access some of the city’s most renowned academics and partners in the field of research and development, including Newcastle University and Newcastle Centre for Cancer.

Now it has set up home in The Biosphere – Helix’s laboratory and office building dedicated to life science innovation, research, development, and commercialisation – in a move which is testament to Newcastle’s status as a leading º£½ÇÊÓÆµ city in those fields.

The move has also allowed the company to recruit from the city’s local talent pool, with half of its workforce coming from the city since its relocation.

Jurek Kozyra, co-founder and chief executive officer of Nanovery said: “Having learnt about the huge challenge around diagnostics with cancer early on in my career, I knew I wanted to start up a company that could work towards developing a more efficient diagnostics solution for serious diseases, with the goal to bring more regular testing to clinicians and patients.